泛福舒胶囊辅治儿童支气管哮喘疗效及其对细胞免疫和炎性因子的影响

摘要

目的：分析泛福舒胶囊治疗儿童支气管哮喘疗效及对细胞免疫和炎性因子水平的影响。方法选择2015年1月—2016年1月在成都市西区医院接受治疗的116例支气管哮喘患儿，按随机数字表法将其随机分成观察组和对照组各58例。2组患儿均接受常规的抗感染、解痉等治疗。对照组患儿应用布地奈德治疗；观察组患儿则在对照组基础上应用泛福舒胶囊治疗。2组患儿均连续治疗3个疗程。比较2组患儿的临床治疗效果以及治疗前后的肺功能、细胞免疫和炎性因子水平的变化情况。结果观察组总有效率为91．4％，高于对照组的72．4％（χ2＝7．036， P ＝0．008）。与治疗前比较，2组 PEF、FEV1、CD3＋、CD4＋、CD4＋／CD8＋、IFN－γ均提高（ t 观察组＝5．951、8．653、22．817、30．252、10．561、25．015， P ＜0．05； t 对照组＝3．739、4．157、7．483、11．610、10．218、10．316， P ＜0．05），CD8＋、IL－4均降低（ t 观察组＝21．327、40．581， P ＜0．05； t 对照组＝6．655、18．065， P ＜0．05），且观察组更为明显（ t ＝2．331、3．266、12．756、14．970、6．812、16．077、17．546、25．408， P ＜0．05）。结论泛福舒胶囊应用于儿童支气管哮喘治疗中，能够提高患者的临床效果，降低炎性因子水平，改善免疫功能，具有重要的临床意义。%Objective To analyze the bronchovaxom capsule in the treatment of children bronchial asthma curative effect and effect on cell immune and inflammatory factor levels.Methods One hundred and sixteen cases of children with bronchial asthma were enrolled, which were treated in hospital from January 2015 to January 2016, and were divided into the observation group (58 cases) and control group (58 cases).The patients of two groups were all treated with conventional treatment, including antibiotics, antispasmodic and so on.The patients of control group were treated with budesonide.On the basis of control group, the patients of observation group were treated with bronchovaxom capsule.The children of two groups were all treated for consecutive 3 courses.Observe and compare the clinic results and changes of pulmonary function, cellular immune and inflammatory factors of two groups.Results The total efficiency of the observation group was 91.4%, higher than 72.4% in the control group (χ2 =7.036, P =0.008).Compared with before treatment, 2 groups of PEF, FEV1 , CD3+, CD4+, CD4+/CD8+, IFN-γwere increased ( t observation group =5.951, t observation group =8.653, t observa-tion group =22.817, t observation group =30.252, t observation group =10.561, t observation group =25.015, P <0.05;t control group =3.739, t control group =4.157, t control group =7.483, t control group =11.610, t control group =10.218, t control group =10.316, P <0.05), CD8+, IL-4 were decreased ( t observation group =21.327, t observation group =40.581, P <0.05; t control group =6.655, t control group =18.065, P <0.05), and the observation group is more obvious ( t =2.331, t =3.266, t =12.756, t =14.970, t =6.812, t =16.077, t =17.546, t =25.408, P <0.05).Conclusion Broncho vaxom capsule used in the treatment of children with bronchial asthma, can improve the clinical effect of patients, reduce the levels of inflammatory factors, improve immune function, has important clinical significance.